CSL ASX: Macquarie brokers say CSL is heading to $500 per share

Already a subscriber?CSL’s share price could almost double to $500 as earnings and margins at its massive blood plasma business rise over the next three years, Macquarie says.

That’s because margins at Behring, CSL’s blood plasma unit, have been below forecasts, growth at its recently acquired iron deficiency group Vifor has stalled, and the company has received poor results in the testing of its cholesterol medication CSL112. “The law of large compounding numbers would make it very hard for CSL to grow their earning per share into a $500 share price without some degree of high sustained inflation, which would inflate all share prices, not just CSL’s.”double-digit earnings growth over the medium term.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

ASX CBA: Macquarie says time to sell Commonwealth Bank, National Australia Bank, Westpac and ANZThe broker has taken a “more aggressive stance” on Australia’s banking sector, saying that share prices don’t match the outlook for earnings.
Source: FinancialReview - 🏆 2. / 90 Read more »

TikToker shares the $500 annual cash boost available to millions through superannuation co-contribution scheme7NEWS brings you the latest local news from Australia and around the world. Stay up to date with all of the breaking sport, politics, entertainment, finance, weather and business headlines. Today's news, live updates & all the latest breaking stories from 7NEWS.
Source: 7NewsAustralia - 🏆 11. / 71 Read more »